ReviewACS omega2020
Empowering Clinical Diagnostics with Mass Spectrometry.
Review in ACS omega, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.
- Biomarkers Identification in the Microenvironment of Oral Squamous Cell Carcinoma: A Systematic Review of Proteomic Studies.International journal of molecular sciences · 2024Pooled it
- Enabling Variant Proteogenomic Assay Development Through a Peptide Target Selection Pipeline and Web Application.Proteomics · 2026Article
- Extraoral Detection of Biomarkers and Pathogens in Saliva: Comprehensive, Panoramic Review.Biosensors · 2026Review
- Self-supervised learning of molecular representations from millions of tandem mass spectra using DreaMS.Nature biotechnology · 2026Article
- The development of an analytical method to evaluate the nitrosamine profile in cooked ham with different preservatives and in rat feces fed with them.Analytical and bioanalytical chemistry · 2026Article
- Development and Validation of a Machine-Learning Deep Plasma Proteome Classifier for Early-Stage Breast Cancer Detection.Breast cancer (Dove Medical Press) · 2026Article
- Advances in mucopolysaccharidosis research: the impact of mass spectrometry-based approaches.Clinical proteomics · 2025Review
- Blood proteomics for quantitative biomarkers of cellular therapies.Biomarker research · 2025Review
- Diagnosis On-Demand: Field Evaluation of Microfluidic Paper Device for the Detection of Asymptomatic Malaria.Analytical chemistry · 2025Article
- Advancements in Breathomics: Special Focus on Electrochemical Sensing and AI for Chronic Disease Diagnosis and Monitoring.ACS omega · 2025Review
- Current Analytical Methods and Challenges for the Clinical Diagnosis of Invasive Pulmonary Aspergillosis Infection.Journal of fungi (Basel, Switzerland) · 2024Review
- Machine learning for precision diagnostics of autoimmunity.Scientific reports · 2024Article
- Streamlining Phenotype Classification and Highlighting Feature Candidates: A Screening Method for Non-Targeted Ion Mobility Spectrometry-Mass Spectrometry (IMS-MS) Data.Analytical chemistry · 2024Article
- A Multiplexed Quantitative Proteomics Approach to the Human Plasma Protein Signature.Biomedicines · 2024Article
- Mass Spectrometry Advancements and Applications for Biomarker Discovery, Diagnostic Innovations, and Personalized Medicine.International journal of molecular sciences · 2024Review
- The expanding diagnostic toolbox for rare genetic diseases.Nature reviews. Genetics · 2024Review
- BERNN: Enhancing classification of Liquid Chromatography Mass Spectrometry data with batch effect removal neural networks.Nature communications · 2024Article
- High-Performance, Low-Cost, Additively Manufactured Electrospray Ion Sources for Mass Spectrometry.Journal of the American Society for Mass Spectrometry · 2024Article
- Serum proteomic biomarkers diagnostic of knee osteoarthritis.Osteoarthritis and cartilage · 2024Article
- Lessons learned: establishing a CLIA-equivalent laboratory for targeted mass spectrometry assays - navigating the transition from research to clinical practice.Clinical proteomics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The unmet need for highly accurate methods of disease diagnosis poses new challenges for developments in laboratory medicine. Advances in mass spectrometry (MS)-based disease biomarker discoveries are continuously expanding the clinical diagnostic landscape. Although a number of MS-based
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.